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Guided by international guest chefs, occupational therapy students learn  
food traditions — planning meals, following recipes, wearing native dress and 
setting the table according to custom. Then, they enjoy the fruits of their labor. 
Students cooked food from Ireland, Asia, India, Poland, Argentina, Colombia and 
Ukraine. Leading the Nigerian cooking lab is Mary Adeniyi (back row, center), 
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 22  Healing arts
COVER  Gabby Carter is among the 
earliest sickle cell patients in the country 
to be treated via an umbilical cord blood 
transplant from an unrelated donor using  
a reduced-intensity conditioning procedure 
refined by Shalini Shenoy, MBBS, MD.  
To learn more, turn to page 10.   
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Preventing Alzheimer’s
 7 Researchers launch the rst clinical trials testing whether new drugs — taken before 
dementia — can slow or stop the disease.
Sickle cell solutions
 10 A novel procedure is gentler on patients and drastically expands donor options for 
children suering from the chronic illness.
Exploring human anatomy                  
16 A hands-on study of a cadaver — in an oen life-changing course — begins the journey 
toward a medical career.
Encore!  
 22 rough a specialty program, clinicians  help performing artists return to their 
abiding passion.
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7 Alzheimer’s trial 
patients first undergo 
brain scans. 
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esearchers at Washington University 
School of Medicine and Imperial 
College London have identified 
the site where the widely used anesthetic 
drug propofol binds to receptors in the brain 
to sedate patients during surgery. 
Until now, it hadn’t been clear how pro-
pofol connects with brain cells to induce 
anesthesia. The researchers believe the find-
ings, reported online in the journal Nature 
Chemical Biology, eventually will lead to more 
effective anesthetics with fewer side effects.
“For many years, the mechanisms by 
which anesthetics act have remained elu-
sive,” explained co-principal investigator 
Alex S. Evers, MD, the Henry E. Mallinckrodt 
Professor and head of the Department of 
Anesthesiology. “We knew that intravenous 
anesthetics, like propofol, act on an impor-
tant receptor on brain cells called the GABAA 
receptor, but we didn’t really know exactly 
where they bound to that receptor.”
Short-acting propofol often is used in  
surgical patients. It wears off quickly and is 
less likely to cause nausea than many anes-
thetics. But the drug isn’t risk-free. Potentially 
dangerous side effects include lowered blood 
pressure and interference with breathing. 
To understand how propofol induces  
anesthesia during surgery, scientists have 
tried to identify its binding site within the 
gamma-aminobutyric acid type A (GABAA) 
receptor on brain cells. Activating these 
receptors — with propofol, for example — 
depresses a cell’s activity. 
Evers’ laboratory teamed up with a group 
at Imperial College led by Nicholas P. Franks, 
PhD, professor of biophysics and anaesthetics. 
The group had created a photoanalogue of 
propofol that behaves in precisely the same 
way as propofol and contains a labeling group 
that permanently attaches to its binding site 
on the GABAA receptor when exposed to a  
specific wavelength of light. 
In creating the analogue, it’s as if the 
researchers put a tiny hook onto the molecule 
so that when it binds to the GABAA receptor,  
it grabs onto the receptor and won’t let go.
“The next step was to extract the receptor, 
cut it into pieces and identify the precise piece 
of the protein where the propofol analogue 
had attached to the receptor. This was the 
tricky step that the Evers group at Washington 
University had perfected,” Franks said.
Evers and Franks believe this technique has 
implications for other types of drugs beyond 
anesthetics, such as psychiatric agents and 
anti-seizure drugs. 
“By understanding precisely what the bind-
ing sites look like on the proteins that induce 
those potential problems, we eventually hope 
to design and select for drugs that have the 
benefits we want without dangerous side 
effects,” Evers said.





Researchers used a photoanalogue of propofol  
to identify where it binds to GABAA receptors.  
The small circles show the site.
“For many years, the 
mechanisms by which 
anesthetics act have 
remained elusive.”
—  A L E X  S .  E V E R S,  M D
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Examining 12 major types of cancer, scientists at Washington 
University School of Medicine have identied 127 repeatedly 
mutated genes that appear to drive the development and pro-
gression of a range of tumors in the body. e discovery sets 
the stage for devising new diagnostic tools and more person-
alized cancer treatments. 
e research, published Oct. 17 in Nature, shows that some 
of the same genes commonly mutated in certain cancers also 
occur in seemingly unrelated tumors. For example, a gene 
mutated in 25 percent of leukemia cases in the study also was 
found in tumors of the breast, rectum, head and neck, kidney, 
lung, ovary and uterus. 
Based on the ndings, the researchers envision that a single 
test — one that surveys errors in a swath of cancer genes 
— eventually could become part of the standard diagnostic 
workup for most cancers. Results of such testing could guide 
treatment decisions for patients based on the unique genetic 
signatures of their tumors. 
While earlier genome studies typically have focused on 
individual tumor types, the current research is among the  
early studies to look across many dierent types of cancer. 
“is is just the beginning,” said senior author Li Ding, 
PhD, of e Genome Institute at Washington University. 
“Many oncologists and scientists have wondered whether 
it’s possible to come up with a complete list of cancer genes 
responsible for all human cancers. I think we’re getting  
closer to that.”
Researchers analyzed genes from 3,281 tumors — a collection 
of cancers of the breast, uterus, head and neck, colon and  
rectum, bladder, kidney, ovary, lung, brain and blood.
Model program  Local youth celebrate the fifth anni-
versary of The SPOT (Supporting Positive Opportunities with Teens). 
Federal and Illinois health officials recently tapped The SPOT as 
a mentor for a similar center in East St. Louis, Ill. Aimed at 13- to 
24-year-olds, The SPOT offers free testing for HIV and sexually trans-
mitted diseases, health care and counseling, social support and more. 







Breast cancer test earns FDA approval
A lab testing kit that estimates the risk of breast cancer 
returning aer anti-hormone treatment has received U.S. 
Food and Drug Administration approval. e technology 
could help standardize breast cancer diagnosis, according to 
School of Medicine researchers, who led the development.
e research team, including collaborators at the 
University of North Carolina, the University of Utah and  
the BC Cancer Agency in Canada, 
designed a test that categorizes breast 
tumors into four main types by looking 
at the expression of 50 genes. Each sub-
type has a distinct genetic signature and 
requires a dierent treatment approach. 
ese subtype data then are combined 
with a standard pathology variable to 
deliver a “risk of recurrence” score that 
predicts the likelihood of that patient’s 
disease returning within 10 years. 
e test, Prosigna, removes some of the 
subjectivity that goes into breast cancer 
diagnosis, which still involves looking at cells under a micro-
scope and, based on visual cues, determining how aggressive 
the tumor is likely to be.
“With this test, we are moving toward a standardized 
diagnosis based on the genetics of the tumor,” said Matthew 
J. Ellis, MB, BChir, PhD, test co-inventor and oncologist at 
Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital 
and Washington University School of Medicine.
Genetic errors found repeatedly 
in 12 of the major cancer types
















Will the cancer return?
“This is just the 
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Washington University School of Medicine has received a 
$7.8 million grant to determine whether the length of time 
red blood cells (RBCs) are stored aects organ failure in  
critically ill children who receive RBC transfusions.
e ve-year grant, from the National Heart, Lung and 
Blood Institute of the National Institutes of Health (NIH), will 
fund a trial involving more than 1,500 criti-
cally ill children who require RBC trans-
fusions at St. Louis Children’s Hospital 
and some 30 other medical centers in 
the U.S. and Canada. e trial will 
be one of the largest studies per-
formed in pediatric critical care. 
“We want to know whether fresh 
red cells can improve outcomes in 
critically ill children,” said Philip 
Spinella, MD, associate professor of 
pediatrics at the School of Medicine  
and a principal investigator in the study.  
“No studies have evaluated whether storing RBCs for more 
than a week aects clinical outcomes for these children.”
e researchers will compare the risk of new or progressive 
multiple organ failure in two groups of critically ill children 
ages 3 days to 16 years randomly assigned to receive RBC 
transfusions as a course of treatment. One group will receive 
RBCs stored for a week or less, and the other will receive 
RBCs stored an estimated average of 21 days. 
Generally, patients who require RBC transfusions receive 
cells stored anywhere from three to 42 days. e standard 
approach is to use those stored the longest rst. 








Mindful approach  Kevin Parks, third-year medical 
student and volunteer with the Young Scientist Program, recently 
shared the wonders of the brain with the general public at Brain 
Works. The event at The Ritz-Carlton, St. Louis, featured hands-on 
demonstrations, including the chance to hold a real human brain, 
and a presentation by Washington University neurosurgeons Eric 
Leuthardt, MD, and Albert Kim, MD, PhD. Among other topics, 
attendees learned about innovative therapies and technologies.
ree highly regarded faculty members in the Department 
of Medicine have been named Alan A. and Edith L. Wol 
Professors in their elds. ey are Daniel C. Brennan, MD, 
Chyi-Song Hsieh, MD, PhD, and Daniel S. Ory, MD.
A bequest by the late Edith L. Wol to enable these and 
other professorships continues the legacy of support for 
medical research that characterized Edith L. Wol’s life and 
that of her husband, the late Alan A. Wol. 
Daniel C. Brennan, MD, is the Alan A. and Edith L. Wol 
Professor of Renal Diseases. He is a professor of medicine 
and director of transplant nephrology at the School of 
Medicine. Brennan joined the faculty in 1993 as the rst 
director of transplant nephrology. He is internationally 
known for his studies on infectious complications of kidney 
transplants, and his research has resulted in new anti-rejec-
tion strategies that have markedly improved kidney trans-
plantation outcomes.
Chyi-Song Hsieh, MD, PhD, the Alan A. and Edith L. 
Wol Professor of Rheumatology, is an associate professor  
of medicine and of pathology and immunology. Hsieh, who 
studies autoimmune diseases, joined the medical school  
in 2005 and has conducted groundbreaking research in  
basic immunology. 
Daniel S. Ory, MD, the Alan A. and Edith L. Wol 
Professor of Cardiology, is a professor of medicine and of cell 
biology and physiology. He is co-director of the BioMed 21 
Diabetic Cardiovascular Disease Center and director of the 
Washington University metabolomics facility. He also is 
director of admissions for the Division of Biology and 
Biomedical Sciences. He joined the faculty in 1995.
Trio of Wolff Professors honored 








Daniel C. Brennan, MD, Chyi-Song Hsieh, MD, PhD, and Daniel S. Ory, MD
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massive online database now 
matches thousands of genes linked 
to cancer and other diseases with 
drugs that target those genes. Some of the 
drugs are approved by the U.S. Food and  
Drug Administration, while others are in  
clinical trials or just entering the drug  
development pipeline. 
The database was developed by identi-
cal twin brothers, Obi Griffith, PhD, research 
assistant professor of medicine, and Malachi 
Griffith, PhD, research instructor in genetics, 
whose interest in pairing drugs with genes 
is as much personal as it is scientific. Their 
mother died of breast cancer 17 years ago, 
weeks before their high school graduation. 
“We wanted to create a comprehensive 
database that is user-friendly, something 
along the lines of a Google search engine for 
disease genes,” explained Malachi Griffith. 
“As we move toward personalized medicine, 
there’s a lot of interest in knowing whether 
drugs can target mutated genes in particular 
patients or in certain diseases, like breast or 
lung cancer. But there hasn’t been an easy 
Matching genes with potential therapies
A
U S E R - F R I E N D L Y  D A T A B A S E
way to find that information.”
Details of the Drug Gene Interaction 
Database were reported online Oct. 13 in 
Nature Methods. The database also includes 
genes involved in Alzheimer’s disease, heart 
disease, diabetes and many other illnesses. 
The Griffiths created the database with a team 
of scientists at The Genome Institute  
at Washington University. 
The database is easy to search and geared 
toward researchers and physician-scientists 
who want to know whether errors in disease 
genes — identified through genome sequenc-
ing or other methods — potentially could  
be targeted with existing drug therapies. 
Additional genes included in the database 
could be the focus of future drug develop-
ment efforts because they belong to classes  
of genes that are thought to make promising 
drug targets.
“Developing the database was a labor 
of love for the Griffiths,” said senior author 
Richard K. Wilson, PhD, director of The 
Genome Institute. “There’s an amazing depth 
to this resource, which will be invaluable to 
researchers working to design better treatment 
options for patients.”
Wilson and his colleagues caution that the 
database is intended for research purposes  
and that it does not recommend treatments. 
The primary purpose of the database is to  
further clinical research aimed at treating  
diseases more effectively.
The free, publicly available database brings 
together information from 15 publicly available 
databases in the U.S., Canada, Europe and Asia. 
To access it, visit dgidb.genome.wustl.edu.
Taylor Institute launch     
An Oct. 1 celebration marked the official 
launch of the Taylor Family Institute for 
Innovative Psychiatric Research. Dedicated to 
developing new and more effective therapies 
for psychiatric disorders, the institute was 
created with a $20 million gift from Andy 
and Barbara Taylor and the Crawford Taylor 
Foundation, the charity of the entire Jack C. 
Taylor family. The institute, housed in the 
Department of Psychiatry, includes members 
from four School of Medicine departments. 
Research initially will focus on neurosteroids, 
naturally occurring chemicals in the brain  
involved in regulating cognition, emotion 
and motivation. For more information, visit 
taylorfamilyinstitute.wustl.edu.
Shown are Taylor Family Institute investigators: (back row, left to right) David Wozniak, PhD; David Reichert, 
PhD; Charles Zorumski, MD; Joe Henry Steinbach, PhD; (middle row) Alex Evers, MD; Douglas Covey, PhD;  
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e National Cancer Institute, part of the National Institutes 
of Health (NIH), has awarded two major grants totaling $26 
million to leukemia researchers and physicians at the Alvin 
J. Siteman Cancer Center at Barnes-Jewish Hospital and the 
Washington University School of Medicine.
e funding helps establish the medical school as a pre-
mier center for innovative leukemia research, with a bench-
to-bedside approach that has the potential to lead to novel 
therapies that improve survival and reduce treatment-related 
side eects.
e rst award is a ve-year, $14.3 million Program 
Project Grant (PPG) in leukemia. e grant initially was 
funded at the medical school in 
2003 and has been renewed 
twice. With new support, 
the scientists aim to 
identify all the genetic 
changes underlying 
the development and 
progression of acute 
myeloid leukemia, the 
most common type of 
acute leukemia in adults. 
is information may 
lead to more personalized 
treatments for patients based 
on the unique genetic and 
molecular signatures of their 
leukemia cells. 
e second award is 
a prestigious Specialized 
Program of Research Excellence (SPORE) grant in leukemia. 
e $11.3 million, ve-year award capitalizes on research 
advances at the medical school to bring new investigational 
treatments into clinical trials.
Timothy Ley, MD, the Lewis T. and Rosalind B. Apple 
Chair in Oncology, is principal investigator of the Program 
Project Grant; Daniel Link, MD, the Alan A. and Edith 
L. Wol Distinguished Professor of Medicine, is principal 
investigator of the SPORE grant.
“ere’s important synergy between the two grants,”  
said Ley. “e PPG focuses on basic research to generate 
ideas, concepts and technologies that can be evaluated in 
clinical trials via the SPORE grant.”
As part of the research, Division of Oncology scientists 
will work closely with researchers at e Genome Institute 
to further explore the genetic basis of leukemia.
NIH grants total $26 million  
for leukemia research
Support for basic science, clinical trials
Evan D. Kharasch, MD, PhD, and J. Evan Sadler, MD, 
PhD, have been elected to the Institute of Medicine of the 
National Academy of Sciences, one of the highest honors 
medical scientists in the U.S. can receive. 
Kharasch and Sadler, both widely 
regarded physician-scientists at 
Washington University School of 
Medicine, are among 70 new 
members and 10 foreign asso-
ciates whose elections to the 
Institute of Medicine recently 
were announced by the 
National Academy of 
Sciences. 
     Members are selected 
based on their professional 
achievements and commit-
ment to service. As members, 
Kharasch and Sadler will devote 
a signicant amount of volunteer 
time on committees engaged in a  
broad range of health-policy issues. 
Kharasch, the Russell D. and Mary B. Shelden Professor 
of Anesthesiology and professor of biochemistry and 
molecular biophysics, is also the vice chancellor for  
research at Washington University.
Sadler is professor of medicine and of biochemistry 
and molecular biophysics and chief of the Division of 
Hematology at the School of Medicine. 
Two elected to Institute of Medicine
 
Investigating the  
genetic origins of acute 
myeloid leukemia
Educational leadership  Michael M. Awad, MD, 
PhD, assistant professor of surgery, now is associate dean for medical 
student education and Valerie S. Ratts, MD, professor in obstetrics and 
gynecology, has been named associate dean for admissions. Awad 
will oversee the medical student curriculum (managing schedules, 
evaluations, assessment, course planning and the Career Counseling 
Office). Ratts will direct all aspects of medical school admissions, 
working to attract, recruit and enroll the best students.
Michael M. Awad, MD, PhD Valerie S. Ratts, MD
6  Washington University School of Medicine
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B Y  M I C H A E L
C .  P U R D Y
PREVENTING
ALZHEIMER’S
Can it be done? A groundbreaking study aims to find out.
TOP: In a 1911 article, Alois
Alzheimer described the symptoms
of his patients and illustrated the
neurofibrillary tangles and amyloid
plaques found during post-mortem
analyses of their brains.
LEFT: Today, scanning confirms
extensive changes in the brain of
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Steps on the journey  School of Medicine researchers have 
made many key contributions along the journey to the new 
DIAN-TU trial. 
e late Leonard Berg, MD, the founding director of the 
university’s Knight Alzheimer’s Disease Research Center, and 
current director John C. Morris, MD, were among the rst to 
assert and prove that Alzheimer’s harms patients’ brains for 
many years prior to dementia onset and memory loss.
Washington University scientists have led the quest for 
new treatments and for biological markers that can identify 
people who seem normal but whose brains are actively being 
damaged by presymptomatic Alzheimer’s disease. 
Researchers have characterized disease markers in cere-
brospinal uid and have tested neuroimaging techniques  
for detecting Alzheimer’s, making it possible to diagnose  
the disease much earlier. 
A long, slow descent  Rare, inherited forms of Alzheimer’s 
are particularly devastating — striking much earlier in life 
than sporadic forms of the disease — with symptoms becom-
ing apparent in some mutation carriers in their 30s or 40s. 
Children who inherit one of the mutations typically show 
signs of Alzheimer’s at about the same age as their parents. 
To expand researchers’ opportunities to work with these 
families, Morris founded the Dominantly Inherited Alzheimer’s 
Network (DIAN) in 2008. is global network generated a 
pool of qualied volunteers and forged a research partner-
ship determined to understand forms of Alzheimer’s caused 
by genetic mutations. 
With the help of DIAN family members, researchers 
created a detailed timeline of the brain’s long, slow descent 
into Alzheimer’s dementia, showing, for example, that brain 
plaques can be detected 15 years prior to symptoms. ese 
plaques are made mostly of amyloid beta. is protein, 
which abnormally accumulates in the brain of people with 
Alzheimer’s, is thought to play a role in brain cell damage 
and death.
Is it possible to curtail Alzheimer’s early stages?A L Z H E I M E R ’S  D I S E A S E  T R I A L
Before damage is done
Two drugs targeting the protein amyloid beta (Aβ) could  
stop it from damaging the brain before any symptoms occur.  
As visualized below, an antibody called solanezumab (s)  
removes soluble molecules of Aβ (yellow). Another antibody, 
gantenerumab (g), binds to and removes larger aggregates of Aβ. 
www. D IANXR . o r g
M O R E  T H A N  A  C E N T U R Y  A G O,  
Alois Alzheimer, a German psychiatrist, 
rst identied the neurodegenerative 
brain condition that came to be known as 
Alzheimer’s disease. 
Finding ways to diagnose and treat this 
devastating disease has frustrated scientists 
and clinicians ever since.
Now the long and hard-fought campaign 
against Alzheimer’s has reached a potentially 
signicant milestone: the launch of the 
rst clinical trials to test whether new drug 
treatments given before dementia can prevent 
the disease. 
e trial is being conducted by the 
Dominantly Inherited Alzheimer’s Network 
Trial Unit (DIAN-TU), led by principal 
investigator Randall J. Bateman, MD, the 
Charles F. and Joanne Knight Distinguished 
Professor of Neurology at Washington 
University School of Medicine.
Learn more about the registry:
s g
~ 1 5  Y R S  P R I O R
Neurofibrillary tangles (gray)  
have already gnarled some tissue; 
amyloid beta protein (yellow) 
deposits in clumps  
~ 2 0 – 3 0  Y R S  P R I O R
Cerebrospinal fluid analysis 
reveals abnormal levels  
of precursor proteins, an 
early warning sign
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Starting the new trial  With the support of these nd-
ings and other groundwork from the DIAN study, Bateman 
established the DIAN Trials Unit. Now, DIAN participants 
and others who have an inherited Alzheimer’s mutation are 
undergoing the rst trials of preclinical treatments that tar-
get amyloid beta. Many of these participants do not have 
any symptoms, but researchers know these patients will get 
Alzheimer’s disease and approximately when they will get it. 
“Trying to prevent Alzheimer’s symptoms from occurring 
is a new strategy, but much of what we’ve learned in recent 
years about Alzheimer’s and the brain has suggested that 
prevention has a signicantly better chance of succeeding 
than treatment aer cognitive impairment,” said Morris, the 
Harvey A. and Dorismae Hacker Friedman Distinguished 
Professor of Neurology. 
e trial is testing two drug treatments  
designed to eliminate amyloid beta from the  
brain at dierent points in the plaque production  
process. Researchers plan to test additional treat- 
ments with dierent mechanisms of action in this  
and future trials. e treatments were nominated  
by the DIAN Pharma Consortium, composed  
of 11 pharmaceutical companies that have been  
advising researchers on the planning of the trial.  
From those nominations, the Alzheimer’s  
researchers chose the trial drugs.
“We believe that the diverse portfolio of drugs and 
approaches of the DIAN-TU trial will accelerate the discov-
ery of an eective treatment for Alzheimer’s,” Bateman said. 
“is trial is possible because of the outstanding support of 
multiple stakeholders, including patients and family mem-
bers, pharmaceutical partners, the Alzheimer’s Association, 
the National Institutes of Health, academic researchers and 
highly dedicated trial operations groups.”
e trial is funded by a unique mix of private and 
public resources, including: major grants from the 
National Institutes of Health (NIH) and the Alzheimer’s 
Association; treatment donations and funding from the 
drugs’ manufacturers Roche and Eli Lilly & Co.; donation 
of a new agent for imaging brain plaques, Amyvid, by Avid 
Radiopharmaceuticals Inc., a wholly owned subsidiary of 
Lilly; and donation by CogState of computerized cognitive 
skills tests to help assess function in participants.
Renewed hope  is initial study involves 210 participants. 
ree of every four will receive active forms of trial drugs; the 
fourth will receive a placebo. Researchers will track biologi-
cal markers of Alzheimer’s in participants’ cerebrospinal uid 
and on brain scans, looking for any indicators that the disease 
process is slowing or stopping.
If successful, scientists plan to move directly into Phase 
III clinical trials to prove that Alzheimer’s can be slowed  
Treatments at later stages have been unsuccessfulIs it possible to curtail Alzheimer’s early stages?
Prevention, the research suggests, has 
a better chance of succeeding than 
treatment after cognitive impairment.
or stopped. e hope is that knowledge gained in the trials 
can be applied to the more common late-onset Alzheimer’s. 
Brent Whitney, 34, of Grove, Okla., is asymptomatic, but has 
an inherited form of Alzheimer’s and is a DIAN participant. 
e lives of his grandmother and 10 of her 13 siblings were 
cut short by the Alzheimer’s gene mutation, and the mutation 
continues to aect succeeding generations of the family.
“e start of this trial is a very exciting moment in 
Alzheimer’s disease research, and it gives me renewed hope 
for a future without Alzheimer’s,” Whitney said. “I hope my 
grandchildren someday learn of this condition in history 
books, like I learned about polio.”
~ 10  Y R S  P R I O R
Protein deposits increase,  
with negative  
effects on cognitive  
functions
~ 5  Y R S  P R I O R
Tissue begins to atrophy  
and shrink; some clinical 
measures can detect  
a functional decline
A L Z H E I M E R ’ S
Difficulties due to memory  
and cognitive loss; impaired 
function in job  
and social activities
3 – 7  Y R S  U N T I L  D E AT H
Marked decline as the person 
becomes increasingly demented, 
culminating in disability  
and finally death
135165_Alzlheimers_7-9_CS6.indd  9 12/9/13  4:25 PM
improving options  for transplants
B Y  S T E V E  K O H L E R










135165_SickCell_10-15_CS6.indd  10 12/9/13  6:05 PM
improving options  for transplants
B Y  S T E V E  K O H L E R
Outlook 11
A reduced-intensity conditioning process — 
gentler than the harsh chemotherapies used 
in the past — will safely prepare Judah Wilks’ 
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N  J U N E  O F  2 0 1 2 ,  6-year-old Gabby Carter reached 
a watershed moment in her young life. Having lived with 
sickle cell disease and its debilitating effects since the time 
of her first medical crisis at 10 months of age, she arrived  
at transplant day. 
       Gabby needed more than 30 blood transfusions and 
made 50 trips to St. Louis Children’s Hospital from her Cape 
Girardeau, Mo., home to manage her condition. Sickle cell 
disease (SCD) is marked by a host of symptoms, including 
sudden pain throughout the body. Although Gabby 
never suffered a stroke, many SCD patients do, and 
the threat is always present.
The transplant itself must have seemed eerily 
anticlimactic. Right there in her all-too-familiar 
hospital room, a bag of what appeared to be oddly 
colored blood hung next to her, and, under the 
direction of Shalini Shenoy, MBBS, MD, its contents flowed 
into Gabby’s veins. No operating room, nary a scalpel, and the 
next day, Gabby was up and moving around. 
If all went as planned, these donated cord blood stem 
cells would find their way to Gabby’s bone marrow and begin 
producing normal, oxygen-carrying red blood cells, replacing 
her defective sickle cells.
Although the procedure was less than dramatic, Gabby’s pre-
conditioning to receive it was finely tuned. And the 18 months 
post-transplant have been a closely monitored “tightrope walk,” 
according to Shenoy. 
Today, Gabby’s sickle cell disease (SCD) is gone — cured. 
Now, her mom, Debbie, says Gabby’s a vibrant 7-year-old  
who has played in the snow, gone swimming and attends 
second grade with her classmates. 
12  Washington University School of Medicine Winter 2013–14
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refining a safer, gentler process 
that promises a long-term fix 
for sickle cell disease
fresh 
starts
first recipients of 
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Gabby is among the earliest sickle cell patients 
in the country to be cured via an umbilical cord 
blood transplant from an unrelated donor using a 
reduced-intensity conditioning procedure rened 
at Washington University School of Medicine.  
e novel procedure is remarkable for two pri-
mary reasons: It is much gentler on patients than 
earlier procedures; and it dramatically will expand 
an extremely limited donor pool. 
upping the odds
A renowned leader in pediatric stem cell transplan-
tation, Shenoy is the Teresa J. Vietti, MD Scholar in 
Pediatrics and directs the Pediatric Bone Marrow 
Transplant Program at St. Louis Children’s Hospital 
and the Alvin J. Siteman Cancer Center at Barnes-
Jewish Hospital and Washington University School 
of Medicine. 
Shenoy is leading a 20-center pilot study 
focused on reduced-intensity cord blood trans-
plants from unrelated donors. e study has a 
safety restriction: three patients must have suc-
cessful transplants before three more can be per-
formed. Following the completion of nine patients, 
Shenoy is hopeful that the pilot study will extend 
to a fully funded national trial by the end of 2014. 
Since Gabby’s transplant, two other children — 
Caitlyn Hill and Judah Wilks — have undergone 
the procedure at St. Louis Children’s Hospital. 
Up until now, treatment options for children 
were limited. One option was to nd an exact 
bone marrow match, but that’s dicult. African 
Americans, who make up the majority of the 
 About 100,000 Americans live 
with SCD. It is the most common 
inherited blood disorder in  
the U.S.
 Sickle cell affects those with 
African, Spanish, Mediterranean 
and Indian ancestry. In the 
U.S., about one in 500 African 
Americans and one in 1,200 
Hispanic Americans are born 
with SCD. 
 SCD occurs when a child 
inherits two sickle hemoglobin 
genes, one from each parent. 
People are born with sickle cell; 
it doesn’t develop later in life 
and it’s not contagious.
 The dysfunctional genes 
produce red blood cells with a 
distinctive sickle shape, jagged 
edges and a brittle structure. 
These cells clump together, and 
intense pain results as blocked 
and damaged arteries starve 
organs and systems of oxygen. 
Anemia is the No. 1 symptom.
 SCD is a chronic illness, but with 
new therapies, many people 
are living more productive lives. 
Life expectancy has increased 
from 14 years to 50 and older.  
things to know about sickle cell disease
sickle cell population, are vastly underrepresented 
in national marrow registries. e other option 
was to use umbilical cord blood from a tissue-
matched sibling free from the disease. 
Nimble newborn cord blood oers signicant 
benets over bone marrow, requiring a less strin-
gent match and fewer cells to eect a cure. Even 
so, tissue-matched sibling donors oen are not 
available. Unrelated cord blood is easier to nd 
because many public banks have made minority 
cord blood donation a priority. However, unre-
lated cord blood transplants simply weren’t very 
successful.
“You have better chances of nding a cord 
match than a marrow,” Shenoy said. “It was 
important for us to nd a successful way.”
5
Checking in post-transplant, 
Caitlyn Hill and her mom, 
Lena, review progress with 
nurse practitioner Monica 
Hente. Inset: Some of the 
meds Caitlyn was taking to 
help her body readjust as  
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improving the process
Cord blood transplants — regardless of source 
— carried an important drawback: they required 
that all of a recipient’s blood-producing cells rst 
be eliminated via high-dose chemotherapy, a toxic 
pre-transplant process known as myeloablative 
conditioning. Despite this, many patients rejected 
cord blood cells from unrelated donors. Even if 
the cells engraed successfully, curing the disease, 
patients oen had unwanted collateral organ  
damage, a high incidence of sterility and liver  
dysfunction. A less toxic option using cord blood 
was needed. 
Shenoy’s reduced-intensity conditioning 
avoids major organ damage. It forces the patient’s 
immune system to accept the new cells — a bal-
ancing act that requires judgment and experience. 
Too little conditioning will cause the donor cells 
to be rejected, but too much can cause prolonged 
immune suppression.
In particular, to prevent rejection, 
the T-cells of the recipient’s 
immune system must be 
depleted, making it pos-
sible to slip in the new 
cells. is is done via 
low-dose chemother-
apy and monoclonal 
antibodies.
 In this method, the 
donated cord blood still 
must be tissue-matched 
for compatibility, but 
importantly, can come either 
from a sibling or from the widely 
available unrelated donor pool.
watching the risks
For the critical month following the cord blood 
transplant, the patient is sustained by transfused 
red blood cells and platelets. Over time, the new 
cells begin to work. SCD patients need as much as 
a year of recovery as the new cells become prolic 
and establish an operative immune system. 
Shenoy monitors what she calls the “big three” 
risks. First is infection. With a downsized old 
immune system and a new one not yet fully func-
tional, infection is a constant threat and must be 
treated promptly.
e second is rejection. Rejection can occur 
when the patient’s remaining immune system 
identies the transplant as foreign and attacks the 
That the reduced-intensity  unrelated cord blood trans-
plants succeed is a tribute to 
Shenoy’s tenacity. The wider medi-
cal community largely abandoned 
reduced-intensity cord blood 
transplants following early failures, 
reverting to myeloablative condi-
tioning with siblings only.
Just eight years earlier, myeloab-
lative conditioning in bone marrow 
transplants from unrelated donors 
also was considered too toxic 
for patients. But Shenoy devised 
a reduced-intensity transplant 
approach. Based on her experience, 
the first unrelated donor bone mar-
row transplant trial for sickle cell 
disease was opened through the 
National Heart, Lung and Blood 
Institute’s Bone Marrow Transplant 
Clinical Trials Network. Shenoy is 
principal investigator for this trial.
Reduced-intensity unrelated 
transplants for sickle cell began 
succeeding with bone marrow, but 
initially failed with umbilical cord 
blood. Shenoy persevered, further 
fine-tuning the pharmaceutical 
cocktail and tweaking the protocol 
until unrelated cord blood trans-
plants also began working.
Despite the disease’s severity 
and the procedure’s complexity, 
Shenoy now achieves successful 
donor cell engraftment using both 
unrelated donor bone marrow and 
cord blood products.
John F. DiPersio MD, PhD, chief 
of the Division of Oncology and 
deputy director of the Siteman 
Cancer Center, hails Shenoy’s work. 
“Her clinical studies will have a 
transformative impact on the 
future success of both related and 
unrelated stem cell transplant for 
children with sickle cell anemia, 
resulting in restoration of normal 
blood production while minimiz-
ing the usual toxicities of unrelated 
stem cell transplants.”
Shenoy’s reduced-intensity 
approach since has been applied 
in bone marrow transplants for 
another condition, thalassemia, 
in a national trial, which used the 
modifed approach successfully 
and included unrelated cord blood 
transplants. Shenoy and others now 
are testing similar methods to treat 
several non-cancerous immune and 
marrow failure disorders.  
Researcher sets national standards
14  Washington University School of Medicine
Shalini Shenoy, MBBS, MD, gives Gabby the OK to stop taking protective  
post-transplant medications — and jump into a life without sickle cells.
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new cells. Shenoy uses DNA tests to determine the 
source — new or old — of the gradual increase in 
red blood cells. She says some mixed chimerism  
— carrying two DNA sets (patient and donor) — 
is acceptable, even long term, but she stays alert  
to any drop in productivity of the new cells.  
e third is rejection’s sneaky counterpart: 
gra versus host disease (GVHD), which can 
quickly ruin everything. In GVHD, the trans-
planted cells’ immune components identify the 
patient’s body as foreign and attack it. e results 
are dicult to treat, and treatment causes further 
immune suppression resulting in a cycle of  
infection and GVHD. 
expecting the best
For many, Gabby included, the year post- 
transplant is tough. She needed 50 medications, 
including 15 IVs for blood pressure control,  
diabetes regulation and steroids to manage GVHD.  
It wasn’t easy avoiding crowds and eating a health-
ful diet. But she followed the regimen and came 
through, with the benets aorded by reduced-
intensity conditioning: no cognitive impairment, 
no liver or kidney dysfunction and no discernible 
fertility damage. Not surprisingly, mom Debbie 
now struggles to maintain the tight control she 
adopted to protect her daughter. 
Because strokes oen recur with SCD and 
damage accumulates over time, Shenoy said  
it’s advantageous to intervene early. But only  
when the risk-to-benet ratio with transplant  
has been shown to be positive. 
at’s why 2-year-old Judah Wilks underwent 
a transplant last fall. Whereas the average age of 
rst stroke for a SCD patient is 9 years, Judah  
suered his rst stroke 10 months ago.
Judah’s parents, Bryce and Maryl Wilks of 
Marsheld, Mo., adopted him and his brother, 
David, from the Democratic Republic of the Congo. 
e family learned of Judah’s SCD only when the 
standard tests that all U.S. infants receive were run 
upon his arrival in this country.  
People of deep faith, the Wilks rmly believe it 
is no accident that they found Judah and that he 
is now part of their Missouri family and close to 
Shenoy’s groundbreaking program. Bryce said of 
the post-transplant future, “We expect the best.” 
at fervent belief — along with Shenoy’s  
attention to balance in applying her novel 
approach to transplant —  
suggests they will  
get nothing  
less. 
Judah Wilks with Megan 
Holtmann, stem cell trans- 
plant nurse coordinator at  
St. Louis Children’s Hospital.  
The conditioning already 
underway, Judah played  
with Megan, read books with  
his brother, hugged his mom 
and mugged for the camera — 
testimony to the general   
     mildness of the transplant  
           preparations.
The standard sickle cell treatment — engrafting a new hemato-
poietic (blood-forming) system created 
from donor cells — has been harsh 
medicine. Donor bone marrow cells 
must exactly match eight cellular 
biomarkers in the recipient. Further, 
recipients endure strong chemotherapy 
to destroy the old system before 
building a new one. By contrast, an 
improved treatment draws from a 
larger pool of cord blood donors  
and uses safer, gentler conditioning.
CONDITIONING     Reduced- 
intensity conditioning agents 
“downsize” the recipient’s 
immune system to avoid 
rejection without causing 
problems during or after  
the transplant.     
TRANSPLANT    The donor cells 
are implanted. Caregivers must 
balance risk factors and manage 
the recipient’s health for a few 
months until the transplanted 
cells establish a stable new  
blood and immune system.
MATCHING   
A successful cord 
blood donation must 
match only five of 
the recipient’s  
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A traditional course of study evolves with 
its field and embraces contemporary 
technologies. From left: anatomy 
instructors Jane Phillips-Conroy, PhD, 
Glenn Conroy, PhD, and Krikor Dikranian, 
MD, PhD.
Exploring  human
A N A T O M Y
135165_Anatomy_16-21_CS6.indd   2 12/9/13   4:50 PM
outlook.wustl.edu
uman anatomy is the flagship course of first-year study.  
Students unravel miles of vessels, dissect masses of tissue, find 
and name interlinking parts and consider functional systems. Dry 
textbook abstractions become viscerally real. During a life-changing 
semester, students ponder the human organism, developing the 
respect and detachment physicians must cultivate in their duties.
Students huddle, four to a cadaver,  
around each stainless steel table. “The first 
day is daunting,” said course master Glenn 
C. Conroy, PhD. “For many, it’s their first 
exposure to death. And it’s a challenging 
and humbling experience to make that first 
incision into the human body.”
Many donors beforehand write letters 
about their lives and medical histories, 
which are placed alongside their bodies. 
“Their last wish was to provide useful 
information to tomorrow’s physicians,” 
Conroy said. “We tell the students, ‘You are 
the instrument through which their final wishes are manifested.’” 
The donors, in a sense, become the students’ first patients.  
Recently renovated, the century-old lab showcases the school’s 
expansive anatomical specimen collection. Anatomists of old would 
marvel at the glowing high-definition wall monitors and iPads. 
Throughout weeks of exploration, feelings of insecurity 
eventually yield to fascination. “You can see the students evolving 
in front of your eyes,”  
Conroy said. 
Practicing specialists 
visit the class to offer clinical 
contexts for the examples 
upon the tables. During exams, 
students must think on their feet when asked questions designed 
to synthesize their analyses of the cadavers.
The course concludes with an evening of reflection; students 
offer memorial poems, essays and musical tributes to the donors.
Through exploring these human bodies, future physicians 
come to better know themselves: a vital passage toward mastering 
the art and science of improving human health. 
Exploring  human
Outlook 17
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Students employ electronic tablets  
and study radiologic anatomy on large  
wall monitors in the renovated lab.
P H O T O  E S S AY  B Y  R O B E R T  B O S T O N
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A quartet of arts specialists, photographed at Powell Symphony Hall in St. Louis:  
Devyani Hunt, MD, Lynnette Khoo-Summers, PT, DPT, Heidi Prather, DO, Aaron Chamberlain, MD
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B Y  D E B  A R O N S O N
HIS YEAR, DEVYANI HUNT, MD, HAD AN EPIPHANY.  
During Dancing in the Streets, a St. Louis outdoor 
festival featuring more than 60 dance companies and 
1,000 dancers, Hunt saw many dancers who might not 
have been on stage without her help. In one instance, Hunt 
realized she had treated 10 of a company’s 18 dancers.  
“It was great to see that,” said Hunt, a physiatrist 
and associate professor in the Department of Orthopedic 
Surgery. “It was an ‘aha’ moment for me that I really am 
making a difference.”   
Along with physical therapist Lynnette Khoo-Summers, 
PT, DPT, Hunt co-directs Washington University’s Medical 
Program for Performing Artists (MPPA). This program helps 
a variety of arts professionals — musicians, dancers, circus 
acrobats, ice skaters, painters and singers — return to 
their beloved stage, abiding passion and, in many cases, 
their livelihood. Frequently, without the help of the MPPA 
team, these unique patients might have to give up the very 
things that animate their lives.
The Medical Program 
for Performing Artists 
rehabilitated Alicia Graf Mack, 
dancer with the Alvin Ailey 
American Dance Theater, now 
on a 24-city tour. 
Professional performance 
demands a finely tuned  
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PPA  C L I N IC I A N S  primarily treat 
local artists but also see performers 
from many dierent tours — “So You 
ink You Can Dance,” Disney on Ice 
and Cirque du Soleil, for example — performing 
locally at e Fabulous Fox eatre, the Blanche M. 
Touhill Performing Arts Center or other venues.
Last year, during the St. Louis production of 
“e Lion King,” one of the lead actors, outt-
ted with a heavy headpiece, suered acute neck 
pain. e role was physically demanding, Hunt 
explains, and the actor no longer could perform in 
costume. In the clinic, Hunt diagnosed him with a 
pinched nerve and treated him to decrease inam-
mation and muscle spasms. Khoo-Summers also 
addressed the muscle spasms, and taped his shoul-
der girdle to provide more support. Within a few 
days, he rejoined the “Lion King” cast.
Hunt once treated a physical comedian from 
Branson, Mo., who injured himself aer doing the 
splits nightly for 15 years. “He wasn’t one to be 
told not to do the splits anymore!” Hunt said.
Performing artists use their bodies 
more intensively and repetitively than 
most people. Musicians might do the 
same movement with their bow arm 
hundreds of thousands of times in 
learning a piece of music. Dancers 
and circus performers repeat 
precision movements day 
aer day. Strain injuries 
are common.
Functioning within “normal” limits simply is 
not good enough. St. Louis Symphony cellist Alvin 
McCall found he could not exert enough force on 
the end of his bow. Because of damage to his ulnar 
nerve, his ngers were sluggish. Initially, McCall’s 
doctor told him that the strength in his le hand 
was “within the normal range.”
 “Diagnosticians and therapists have to under-
stand the demands you make on your body,” said 
McCall’s wife, Anna Lackschewitz, who is also 
a professional musician. “Lots of doctors just 
shrugged o his concerns about needing a higher 
level of performance.” Another doctor told him 
‘wait and see.’ ey have no appreciation that this 
is our livelihood.” 
Not so with the MPPA, where McCall found 
support and help to strengthen weak muscles and 
adapt his playing style. Lackschewitz and McCall 
were so happy with how McCall was treated that 
they referred all four of their children, two who 
now dance professionally. Recently, Lackschewitz, 
principal violist of the Fox eatre Orchestra, 
underwent therapy for a pinched nerve in her neck.
The MPPA was established in 1988 by the late Jerome 
Gilden, an orthopedic specialist in the School of 
Medicine and Barnes-Jewish Hospital. He retired 
in 1998, but, in 2004, the program was revived 
by Hunt, Khoo-Summers and Heidi Prather, DO, 
orthopedic surgery professor and chief of the 
section of physical medicine and rehabilitation. 
Prather and Hunt are physiatrists — specialists in 
physical medicine and rehabilitation who focus 
on non-surgical musculoskeletal care. ey excel 
at linking symptoms to root causes and, unlike 
orthopedic surgeons, are not body-part specic.
Two years ago, Aaron Chamberlain, MD, a 
shoulder and elbow surgeon and assistant profes-
sor of orthopedic surgery, joined the group. 
Because of their experience as performing artists, 
they bring zeal and understanding to their clinical 
work: Hunt and Khoo-Summers as dancers, 
Prather on trumpet and Chamberlain on violin. 
“We understand where they (the artists) are 
coming from,” said Khoo-Summers, who danced 
professionally in Chicago before injuring her 
knees. Now an assistant professor in the Program 
in Physical erapy and the Department of 
Orthopedic Surgery, she found her niche in reha-
bilitating performing artists. “We understand that 
need to perform, to make your body do things it 
is not built for. Most oen, if you go to clinicians 
who don’t understand that need to perform,  
they’ll say, ‘If it hurts to dance, don’t dance.’”
Poetry in motion:  
Devyani Hunt, MD (left), 
and Lynnette Khoo-
Summers, PT, DPT, evaluate 
Marcus Johnson, a Webster 
University dance major  
and instructor at  















135165_Arts_22-25_CS6.indd   24 12/11/13   4:06 PM
outlook.wustl.edu Outlook  25
Together, Hunt and Khoo-Summers diagnose 
problems by observing patients in motion. In 
addition to traditional exercise equipment, such 
as treadmills, an elliptical, bikes and a universal 
gym, the physical therapy clinic boasts a ballet 
barre and special ooring for dancers.
 “If you test performing artists in the oce in 
standard fashion to see if they have good muscle 
strength, their strength will be ne,” she said. 
“But if they can’t maintain the posture they need 
because of fatigue, then you have to develop a 
training program to work more toward endurance 
and posture retraining.”
While the MPPA physicians’ eorts help 
decrease symptoms, Khoo-Summers corrects 
the movement impairments that are causing the 
symptoms. is is done by attaining better align-
ment, correcting muscle imbalances, building 
stamina and developing adaptive strategies. 
“e MPPA is cutting edge — 
designed to maintain high levels 
of performance in those who push 
the limit of what is physically pos-
sible on a sustained basis,” said 
Richard Gelberman, MD, the Fred 
C. Reynolds Professor and chair 
of the Department of Orthopedic 
Surgery. “e clinicians are to be 
congratulated for bringing excep-
tional care for this ultra-commit-
ted population to St. Louis and  
to our region.”
Not surprisingly, the eld of performing arts  
medicine is a small and tight-knit community. 
ere are fewer than 50 such programs nationwide 
and many have sprung up in cities with major per-
forming arts centers. Harkness Center for Dance 
Injuries, for example, was founded in 1989 in 
response to the New York dance community’s criti-
cal need for specialized and aordable health care. 
Washington University’s program, while not one  
of the nation’s largest, is well known and respected.  
“Washington University’s program in perform-
ing arts is a wonderfully integrated and multi-
disciplinary program,” said Monica Rho, MD, 
assistant professor of physical medicine and reha-
bilitation at Northwestern University’s Feinberg 
School of Medicine. “Dr. Hunt worked hard to 
develop a clinic where both she and Lynnette  
co-evaluate and co-treat the patient. e coordina-
tion of these services places the performing artist’s 
needs rst and makes Washington University’s 
program a model to emulate.”
Such coordination may 
sound simple, but most pro-
grams cannot coordinate co-evaluations, said Rho, 
who also sees performing artists in her practice. 
Because it’s critical for these artists to maintain 
their performance schedules, the MPPA team 
oers same-day appointments whenever possible.
Besides working in the clinic, Hunt or Khoo-
Summers oen are on-call or backstage at perfor-
mances. Recently, Khoo-Summers accompanied 
Dance St. Louis pro bono on a three-city tour. 
Because most patients have chronic overuse 
injuries, it’s important that artists adopt preventive 
strategies early in their careers. e MPPA holds 
outreach programs with young dancers, musicians 
and circus performers, recently leading a sympo-
sium for Wester University’s Department of  
Music and Community Music School. 
But no matter how much prevention they 
preach, injuries will occur. With proper interven-
tion, however, injuries don’t have to result in a 
sidelined career; performing artists can get back 
on the road and back to following their passion.
Warming up for a 
Metropolitan Orchestra 
of St. Louis concert: Alvin 
McCall, St. Louis Symphony 
cellist, and his wife, Anna 
Lackschewitz, principal  
violist of Fox Theatre 
Orchestra, who both  
were treated through  
the Medical Program for 
Performing Artists. 
“We understand 
that need to 
perform, to  
make your body 
do things it is  
not built for.”  
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and infectious diseases research has become one of the largest areas 
of concentration within the School of Medicine. As new diseases 
appear, there is an ever-greater risk of rapid transmission and spread 
of infection. By traveling to foreign countries to provide basic 
health care or by oering programs in St. Louis aimed at preventing 
sexually transmitted diseases, our faculty, students and sta are 
dedicated to making a dierence — locally, nationally and globally. 
 Research in the gut microbiome, hospital-acquired infections, 
and parasitic diseases are but a few examples of the breadth and 
depth of our leadership. e potential to solve some of the most 
vexing questions of population health is growing as our research 
teams forge a rapid pace toward discoveries.
 Private philanthropy is essential to advance the initiatives 
described in the following pages.
 Partner with us in support of these initiatives.
Improving health is among the world’s most pressing challenges, 
The global reach of 
Washington University 
extends to sub-Saharan 
Africa. Mark Manary, MD, 
the Helene B. Roberson 
Professor of Pediatrics, 
developed a revolutionary 
peanut butter-based 
therapeutic food to 
combat severe childhood 
malnutrition. A proven 
lifesaver with a 95 percent 
recovery rate, the blend has 
become standard treatment 
worldwide.
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Hospital-acquired infections (HAIs) remain 
a signicant cause of illness and death. Too fre-
quently, bacteria or other microorganisms lurk-
ing on medical devices, bed rails, a bandage or a 
caregiver’s hands nd their way into a patient’s 
body via a wound, catheter, ventilator or invasive 
procedure. 
School of Medicine researchers have developed 
infection surveillance and control 
guidelines that have been adopted 
worldwide.
Despite these measures, new 
virulent, antibiotic-resistant patho-
gens such as methicillin-resistant 
Staphylococcus aureus (MRSA) and 
Clostridium dicile have emerged. 
People are living longer, but also are 
more susceptible to HAIs —through 
advances in cancer therapy, the 
use of immunosuppressants and 
long-term management of multiple 
chronic diseases. “e key to pre-
venting the spread of infections is 
vigilance and attention to strict patient care guide-
lines,” said Victoria J. Fraser, MD, the Adolphus 
Busch Professor and chair of the Department of 
Internal Medicine and a world-renowned infectious 
diseases expert.
Among critical advances made by the medical 
school’s infectious disease research team and BJC 
HealthCare Infection Prevention Consortium:
• Safer IV insertion techniques and use of 
the antibacterial antiseptic chlorhexidine to 
lower the risk of bloodstream infections. In 
10 years, central line-associated bloodstream 
infections in the U.S. decreased 60 percent.
• Standardized procedures to reduce surgi-
cal site infections, including improved hand 
hygiene, skin antiseptic use, clippers instead 
of shaving, perioperative glucose control, 
better temperature control in the operating 
room and precise timing of antibiotic use. 
• Improved patient management policies — 
including elevating the head of hospital 
beds, use of disinfectant mouthwashes and 
standardized order sets to wean patients o 
ventilators and sedatives — which reduced 
ventilator-associated pneumonia in ICUs. 
is campaign, named “Whap VAP,” subse-
quently was replicated across the country. 
Our ability to advance research, recruit the  
best individuals and train health care workers  
to protect patients is greatly helped by private  
philanthropy. 
Victoria J. Fraser, MD, and her team lead infection control training programs in health care and community settings.




control guidelines that have
been adopted worldwide.








Vicky Fraser with  
residents in hospital
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Interest in global health among U.S. medical 
students has grown dramatically. But, only a small 
fraction of students who work overseas during 
medical school will pursue careers in interna-
tional health.
Faculty say it is clear, however, that early inter-
national experiences can have long-term impact on 
medical students and their future patients. Global 
training broadens students’ perspec-
tives on disease prevention, care 
delivery and health care systems. 
e Forum for International 
Health and Tropical Medicine 
(FIHTM) is a student-led group 
devoted to promoting interest and 
understanding of global health at 
the School of Medicine. With sup-
port from the dean’s oce and the 
Washington University Medical 
Center Alumni Association, FIHTM 
annually sponsors one- to two-
month overseas electives for 25 stu-
dents and spring break experiences 
in the Navajo Nation and Central America.
FIHTM fellows participate in a wide range of 
research and clinical activities, such as studying 
tuberculosis in India, working on malaria preven-
tion in rural Uganda and examining respiratory 
disease in stonemasons in Colombia. 
“Many of our students say their international 
experience was life-changing,” said Gary Weil, 
MD, professor of medicine and faculty adviser to 
FIHTM. “ey quickly learn to adjust to reduced 
resources and they see that culture, behavior and 
environment dramatically aect health, outcomes 
and the delivery of care.”
Working with diverse populations in low-
resource settings requires students to rely heavily 
on physical exams and the patient’s history to 
make a diagnosis. ese electives oen strengthen 
“so” skills, such as compassion and cultural 
sensitivity, which are valuable regardless of where 
students practice.
“It taught me how to establish a rapport with 
patients in spite of a language barrier and to see 
things from another cultural perspective,” said 
Christelle Samen, a second-year medical student 
who completed a rotation in Guatemala.  
Student demand for these experiences outpaces 
the resources of FIHTM. Private philanthropy can 
support summer internships around the globe.
“ere’s a growing interest in global health 
issues, and many of these issues are relevant to 
U.S. medical practice and policy,” Weil said. 
“rough FIHTM, the medical school is preparing 





doctors who will work
to change the world.”
— GARY WEIL, MD
With support from FIHTM, students designed and implemented a diabetes prevention program in Majuro, Republic of the Marshall Islands.
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A catalyst for innovation, the Global Health 
Scholars in Medicine program takes residents 
out of the academic medical setting with its latest 
technologies and collaborative, multidisciplinary 
teams and places them in underresourced parts  
of the world.
On these month-long rotations, medical resi-
dents hone their skills — overcoming language 
barriers, broken equipment and cul-
tural sensitivities. Oen, they work 
without the benet of a translator, 
attending physician or nearby lab. 
ese new physicians gain a 
global mindset, understanding not 
only disease, but also the impact of 
culture and poverty on public health.
Ten residents are selected yearly 
to participate in the highly competi-
tive program administered by the 
Department of Internal Medicine. 
e program began in 2007 with 
support from Jack Ladenson, PhD, 
the Oree M. Carroll and Lillian B. 
Ladenson Professor of Clinical Chemistry. 
Ladenson and David Windus, MD, professor of 
medicine, led residents to Eritrea and Bhutan to 
create diabetes education and disease manage-
ment programs. 
Now it includes more faculty and sites in 
Honduras, India, Japan and Guatemala. Also,  
the program oers a locally based “international” 
rotation: students work with refugees and the 
homeless in St. Louis — people they might not 
typically see during an inpatient rotation — at 
Family Care Health Centers and Casa de Salud. 
Scholars conduct research, develop outreach 
initiatives and share best practices. 
“It strengthens several aspects of our curricu-
lum, including training in cultural sensitivity and 
preventive care,” said Melvin Blanchard, MD, 
FACP, chief of the Division of Medical Education. 
“As a university with a global view, we hope that 
our trainees develop an appreciation for the wider 
world in which we live and become engaged in a 
manner that advances longevity and a high quality 
of life in our immediate community and abroad.”
Rachel Kilpatrick, MD, an endocrinology fellow 
at the School of Medicine, nished a rotation in 
Eritrea and now hopes to work with Hispanic 
immigrants. “I’m motivated to work with the 
underserved here in the United States, particularly 
with immigrant populations that may have di-
cult access to care,” she said. “My time as a Global 
Health Scholar was one of the most valuable  
experiences of my entire medical training so far.”
Worldview of health
These new physicians
gain a global mindset,
understanding not only
disease, but also the
impact of culture and
poverty on public health.
Global Health Scholars learn sensitivity to other cultures and develop solutions in resource-limited environments, such as this ICU in Guatemala City.
135165_MAD_26-36_CS6.indd  30 12/9/13  5:07 PM
outlook.wustl.edu Outlook  31
Ending malnutrition
International leaders in addressing childhood 
malnutrition, Washington University researchers 
are working to devise innovative solutions.
Jerey Gordon, MD, the Dr. Robert J. Glaser 
Distinguished University Professor and director 
of the Center for Genome Sciences and Systems 
Biology, leads an international team of scien-
tists trying to understand how gut microbes (the 
“microbiota”) help determine nutri-
tional status.
Recent study ndings point to 
a role for the microbiota in child-
hood malnutrition. e research, 
published in the journal Science, 
involves 317 sets of twins in Malawi 
followed from birth to age 3. 
Childhood malnutrition is all 
too common, and scientists won-
der why some children are aicted 
but not others, even those in the 
same household who eat the same 
foods. Gordon and his team focused 
on twin pairs in which one child 
remained healthy and the other became mal-
nourished. is ‘discordance’ occurred equally in 
fraternal and identical twins, suggesting an under-
lying factor besides human genetics. So the team 
turned to the microbiota.
erapeutic food interventions reduced  
mortality in children with severe undernutrition, 
but healthy growth was not completely restored 
and proper neurodevelopment lagged. 
e team found that the microbiota of 
malnourished children appeared immature. 
erapeutic foods helped, but once they were 
stopped, the immature state reappeared. 
By transplanting microbiota from twins into 
formerly sterile mice, the researchers showed that 
the combination of immature microbiota from a 
malnourished child and a Malawian diet produced 
disease in recipient animals; this was not the case 
when mice received a healthy child’s microbiota. 
eir work provides a microbial view of human 
postnatal development and suggests that healthy 
growth requires a properly maturing microbiota. 
An important implication is that prolonged 
food-based interventions and/or addition of gut 
microbes may be needed for durable repair of 
microbiota immaturity in childhood malnutrition 
and improved clinical outcomes. 
“With support of the Bill & Melinda Gates 
Foundation, we are studying the gut microbiota in 
malnourished children living in other low-income 
countries, and working to develop new types of 
safe, eective interventions to treat and ultimately 
prevent this devastating disease,” Gordon said.
Researchers believe there
is a link between gut
microbes and the diets of
malnourished children.
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Washington University has broad research 
focused on the viral causes of infectious disease. 
Stephen Beverley, PhD, is researching viruses 
that make parasitic diseases more dangerous. 
In doing so, Beverley, the Marvin A. Brennecke 
Professor and chairman of the molecular micro-
biology department, is forging a pathway in his 
eld, which he calls “parasite virology.”    
In 2011, Beverley’s team, working 
with scientists at the University of 
Lausanne in Switzerland, found  
that a particular virus increased  
the severity of a parasitic disease 
called Leishmaniasis. 
About 12 million people are 
infected worldwide with this poten-
tially lethal disease, and 2 million 
new cases develop each year. 
“e fact that there was a viral 
target within the Leishmania para-
site immediately led us to thinking 
that an antiviral therapy could  
control the spread and impact of  
the disease,” Beverley said. “We’re now exploring 
several leads in this area.”
Michael Diamond, MD, PhD, professor of 
medicine and an expert on West Nile virus, is  
part of a new multi-institution collaboration  
looking for similarities in how humans respond  
to three potentially lethal viruses.  
e National Institutes of Health (NIH)  
study will focus on West Nile, Ebola and inu-
enza, using advanced computational models  
to nd common traits. Diamond expects that  
nding similarities could lead to new, more  
eective treatments. 
David Wang, PhD, associate professor of  
molecular microbiology and pathology and  
immunology, was part of an important team in 
2003 that successfully hunted down the severe 
acute respiratory syndrome (SARS) virus. 
Emerging viruses pose constant threats to  
public health. Today, Wang continues eorts  
to identify and characterize novel viruses. 
His current research attempts to understand 
why 70 percent of viral encephalitis cases and 
30 percent of respiratory tract infections defy 
the most sophisticated diagnostic tests now used 
— suggesting that unknown agents likely are 
involved in the pathogenesis of these diseases.   
Philanthropy plays a vital role in funding  
fellowships and research opportunities. Support 
from donors is critical to our continued leader- 
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Infectious Diseases and Global Health
	 n Endowed professorships for specic departments  
 or diseases  
 n Endowed research funds for specic departments  
 or diseases 
 n Endowed gis to be recognized by naming an institute,  
 center or research laboratory
 n Annual or endowed fellowship support  
 for physician-scientists
 n Expendable support for three- to ve-year pilot projects
 n Annual unrestricted support
The Brain
Cancer and Personalized Medicine   
Diabetes, Heart Disease and Obesity  
Annual or endowed fellowship support  
for graduate and physician-scientists  
The Annual Fund
Together,  
 we can change lives.
Improving global health is among the world’s most
pressing challenges. Please consider funding this or other
opportunities to advance human health.
For information















See inside back cover
Leading Together The Campaign for Washington University
135165_MAD_26-36_CS6.indd  33 12/9/13  5:08 PM
classnotes
1940 S 
Carl Woolsey, MD 43, is retired and living in 
Salt Lake City. He enjoys “being with his 
family, drinking whiskey and telling lies  
with friends, relatives and neighbors.” He is 
proud to have three generations of OB/GYNs 
in the same family practice and hospital.
1950 S 
Bernice Oshita, NU 50, was honored by 
The American Red Cross as a “Volunteer of 
the Week” for contributing 10,716 service 
hours to the Tripler Army Medical Center 
in Honolulu. She describes herself as the 
“gofer,”  lending a hand as needed in the 
office and helping nurses.
Rudenz “Rudy” Douthat, MD 54, was 
honored at the American College of 
Emergency Physicians (ACEP) Scientific 
Assembly as one of two surviving found-
ers of emergency medicine and ACEP.
1960 S 
Ronald Evens, MD 64, has been appointed 
chairman of the Board of Regents for the 
National Library of Medicine (NLM), the 
world’s largest medical library. The NLM 
board guides the library as it manages the 
worldwide flow of medical information.
Josh Grossman, MD 65, colonel (retired), 
U.S. Army Medical Corps, MD, FACP,  spoke 
to the Washington County Bar Association 
on “Landmark Medical Ethical Matters.”
Michael Treister, MD 67, attended the 
National Flute Association annual con-
vention. As a previous chair and current 
member of the Performance Health Care 
Committee and Editorial Board, Treister 
enjoyed getting away from the office to 
“jam” with other flautists.
1970 S 
Francisco Garriga, MD 70, published  
Tell Me How You Die Easy, a book aimed at 
educating medical and nursing students 
on the importance of compassionate care.
Scott Frankel, MD 79, an allergy special-
ist with Kansas City Allergy & Asthma in 
Overland  Park, Kan., was named a  
“Top Doctor” by U.S. News & World  
Report and Castle Connolly Medical Ltd.
Cecil Holliman, MD 79, presented the 
opening plenary lectures on “Trauma 
System Development” and “Prehospital 
Trauma Triage” at the 2013 International 
Conference and Training on Emergency 
Trauma Care held in Vietnam last March. 
Holliman is president-elect of the 
International Federation for Emergency 
Medicine.
1980 S 
David Baltzer, HA 81, has been elected 
to the Board of Directors of the Missouri 
Health Executives Group, the state chapter 
of the American College of Healthcare 
Executives, and will chair the communica-
tions committee.
Ayse Kilfoy, DE 87, was named to St. Louis 
Magazine’s “Top Dentists” list for the fifth 
consecutive year.
1990 S 
Kirk Gasper, MD 93, was promoted to 
U.S. Navy captain and served as a senior 
medical officer at the Naval Branch Health 
Clinic in Bahrain. In August, he returned 
to Oak Harbor, Wash., to his family, which 
includes Michele (Francoeur) Gasper, 
MD 93, who also serves in the Navy.
Tadd Pullin, HA 94, GR 94, was named 
senior vice president of marketing and 
strategy development at the Nebraska 
Medical Center in Omaha, where he pro-
vides senior oversight for marketing, stra-
tegic planning and human resources.
Brett Kissela, MD 95, has been appointed 
the Albert Barnes Voorheis Chair of 
Neurology and Rehabilitation Medicine at 
the University of Cincinnati (UC) College 
of Medicine and UC Health, effective Jan. 
1, 2014. He joined the neurology depart-
ment as an assistant professor in 2000.
2000 S
Marc Herant, MD 00, will spend the next 
two years in Rwanda as an adviser to the 
Ministry of Health.
Elizabeth Foglia, MD 05, is completing 
a neonatology fellowship at Children’s 
Hospital of Philadelphia this fall and will 
transition to a faculty clinical research 
position and study neonatal resuscita-
tion. Her husband, Ted Satterthwaite, 
MD 06, works in imaging research in the 
Department of Psychiatry at the University 
of Pennsylvania. They recently welcomed 
their third child.
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Distinguished Alumni Scholars honored  Four first-year  
medical students recently were honored as Distinguished Alumni Scholars. Each  
scholarship is named to honor an alumnus or alumna who has served on the School 
of Medicine faculty. Distinguished alumni honorees and scholars, from left: Jeffrey 
Marinshaw; William F. Stenson, MD 71; Kevin Li; Leonard Bacharier, MD 92; Jordan 
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Leana Wen, MD 07, co-authored the book 
When Doctors Don’t Listen: How to Avoid 
Misdiagnoses and Unnecessary Tests. 
She is an attending physician and director 
of patient-centered care research in the 
Department of Emergency Medicine at 
George Washington University.
In Memory 
Ernesta Grace Mira, NU 41
 Mira died Thursday, Aug. 1, 2013, at age 
95. Mira grew up in Roodhouse, Ill., and 
dreamed of becoming a nurse. Upon 
graduating from Washington University, 
she was called to active duty in the Army 
Nurse Corps and sent to O’Reilly General 
Hospital in Springfield, Mo. Later, she 
opened a medical practice in Alton, Ill., 
with her husband Joseph Mira, MD 41, 
who preceded her in death.  
Charles Nicolai, LA 43, MD 46, HS
 Nicolai died Friday, May 31, 2013, at the 
age of 91. He completed undergradu-
ate and medical degrees at Washington 
University before serving in the U.S. Navy 
Medical Corps from 1947-49. After the 
war, he returned to the university and co-
founded the Division of Urology in 1953. 
For a time, Nicolai practiced urology at 
Missouri Baptist and Deaconess hospitals, 
serving as chief of staff and chief of urol-
ogy. Nicolai returned to the School of 
Medicine in 1990 in the office practice 
of Urology and Prostatic Cancer research 
until retiring in 2005. He was a found-
ing and life member of the Society for 
Pediatric Urology, a fellow of the American 
Academy for Pediatrics and a consultant 
to the Shriners Hospitals for Children. He 
was a 32 degree Master Mason K:C:C:H. 
Moolah Shriner.
Margaret Burge McChesney, MD 49
 McChesney died Friday, April 26, 2013, in 
Newport News, Va. She is remembered as 
a devoted wife, mother and pediatrician. 
David Reed Holmes, MD 51
 Holmes died Sunday, March 17, 2013, 
at age 90. A graduate of Missouri State 
Teachers College in Springfield, Mo., 
Holmes joined the U.S. Navy during World 
War II and became a pilot. He attended 
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the School of Medicine and opened a 
general practice in Warrensburg, Mo. He 
later returned to Washington University 
to become an OB-GYN, completing an 
infertility fellowship. For 30 years, Holmes 
practiced as an OB-GYN in Springfield, 
delivering 9,000 babies. At one point, 
he was the only infertility specialist in 
Southwest Missouri. 
Henry Baker Lorentz, DE 53
 Lorentz died Tuesday, Feb. 12, 2013, at 
Peace Hospice in Great Falls, Mont. He was 
86. Lorentz earned a bachelor’s degree 
from Montana State College and attended 
Washington University Dental School. 
During World War II, he served as a naval 
air gunner and later joined the Army 
Dental Corps. A practicing dentist for 40 
years, Lorentz was elected president of 
the Montana State Dental Association and 
was honored for distinguished service by 
the Montana State Dental Society. 
Mitchell E. Goldenberg, LA 52, MD 55
 Goldenberg, a plastic and reconstructive 
surgeon in Northwest Indiana for more 
than 40 years, died Sunday, Jan. 20, 2013, 
at age 81. After attending Washington 
University for undergraduate and medical 
studies, he completed a general surgery 
residency at Albert Einstein Medical 
Center in Philadelphia, a plastic surgery 
residency at Meadowbrook Hospital in 
Hempstead, N.Y., and a hand surgery fel-
lowship at Memorial Sloan Kettering. He 
served as a U.S. Army captain and as a 
physician in a MASH unit in Korea. 
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If you wish to make a tribute gift in honor  
of any of the above alumni or faculty, please 
contact: Pamela Buell, Washington University 
Medical Alumni and Development, Campus Box 
1247, 7425 Forsyth Blvd., Suite 2100, St. Louis MO 
63105-2161, (314) 935-9691.
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Gregory Clawson Rosenberger, PT 59
 Rosenberger, a physical therapist for 34 
years in Indiana, Iowa and Wisconsin, 
died Monday, June 17, 2013, at age 82. 
He served in the U.S. Army for three years 
during the Korean Conflict. Rosenberger 
earned a bachelor’s degree in physical 
therapy from Washington University and 
a master’s degree in public health from 
the University of Michigan. He particularly 
enjoyed working with elderly patients. 
O. Michael Colvin, MD 61
 Colvin, a prominent cancer researcher, 
died Saturday, March 16, 2013. He was 
77. Born in Princeton, Ind., he gradu-
ated from Indiana University in 1957 and 
Washington University School of Medicine 
in 1961. He completed an internal medi-
cine internship and residency at Johns 
Hopkins University. Following a fellowship 
at the National Cancer Institute, Colvin 
worked at Johns Hopkins for 30 years  
— as a professor of medicine and phar-
macology, director of the pharmacology 
division, research director for the oncology 
center and associate dean for research. 
Colvin later moved to Duke University, 
becoming director of its cancer center 
and the William W. Shingleton Professor of 
Cancer Research and professor of pharma-
cology and cancer biology. 
Perry Dyson Inhofe II, MD 88, HS 89
 Inhofe died unexpectedly Sunday, Nov. 10, 
2013, of injuries sustained from a plane 
crash. He was 52. Inhofe completed an 
undergraduate degree, first in his class, 
in biomedical and electrical engineering 
from Duke University in 1984. He earned a 
medical degree at Washington University 
and completed an internship at Barnes 
Hospital and residency at the University 
of Oklahoma College of Medicine, 
Orthopedic Surgery and Rehabilitation. 
Inhofe met his wife, Nancy Rader Inhofe, 
MD, at Washington University when he 
rotated through the Pediatric Emergency 
Department. They were married in 1989. 
Inhofe was an active orthopedic surgeon 
at Central States Orthopedics in Tulsa, 
Okla. He was the son of U.S. Sen. James 
Inhofe with whom he shared a love of fly-
ing. He is remembered as a devoted and 
loving husband, father, son and physician.
Andrew Zupan, LA 84, MD 92, GM 92
 Zupan, a pediatrician in St. Peters, Mo., 
died Friday, Feb. 15, 2013. He was 50. 
Originally from Columbus, Ohio, Zupan 
completed undergraduate studies at 
Washington University and earned an 
MD/PhD from the School of Medicine. 
Zupan completed a pediatrics residency at 
Cincinnati Children’s Hospital. He practiced 
pediatrics in Batesville, Ind., and later in 
Washington and St. Peters, Mo.
Faculty 
Bernard Becker, GR 90
 Becker died Wednesday, Aug. 28, 2013, 
at his Central West End home. He was 
93. Becker grew up in Brooklyn, N.Y., and 
graduated from Princeton University and 
Harvard Medical School. He trained as a 
U.S. Army psychiatrist during World War 
II and later in ophthalmology at Johns 
Hopkins University. Becker is largely 
known for his work to find glaucoma 
treatments. During the 1950s, he helped 
Washington University medical school 
build its Department of Ophthalmology 
and Visual Sciences, and headed it for 35 
years. Additionally, he helped establish the 
National Eye Institute. Becker donated a 
600-volume collection of medical books  
to the medical school and, in 1995, the 
medical library was renamed in his honor. 
Thomas B. Ferguson, HS 57
 Ferguson, professor emeritus of car-
diothoracic surgery, died Sunday, May 
26, 2013, at age 90. A pioneer in heart 
surgery, Ferguson helped bring the first 
heart-lung machine to St. Louis in the 
late 1950s. In 1958, he and his colleagues 
performed Washington University’s first 
open-heart surgery with the aid of the 
new heart-lung pump. A graduate of the 
Duke University medical school, Ferguson 
trained in surgery at Duke, Barnes Hospital 
and Washington University. Except for four 
years in private practice, Ferguson spent 
his career at Washington University, train-
ing residents and fellows in cardiothoracic 
surgery and serving on the admissions 
committee. He was president of the 
American Association for Thoracic Surgery 
and the Society of Thoracic Surgeons, of 
which he was a founding member. 
Elmer Brown Jr., MD 50
 Brown, a distinguished hematologist 
and emeritus professor of medicine, died 
Saturday, Sept. 8, 2012, at his home in 
Dana, N.C. He was 86. A native of New 
York City, he attended Oberlin College, 
then earned a medical degree from 
Washington University. After a residency 
at Columbia-Presbyterian Center in New 
York, Brown served two years in the U.S. 
Naval Medical Corps. Afterward, he trained 
in the Division of Hematology at Barnes 
Hospital, serving for nine years as division 
chief before becoming associate dean for 
postgraduate education. 
Charles Ward Parker, MD 53
 Parker died Tuesday, April 23, 2013, at his 
home in Webster Groves, Mo. He was 83. 
His pioneering research helped improve 
treatment of allergies and asthma. Parker, 
who founded the university’s Division 
of Allergy and Immunology in the early 
1960s, served on the faculty for more than 
four decades. Parker attended Washington 
University for undergraduate and medical 
studies. Afterward, he spent two years in 
the U.S. Navy before completing an inter-
nal medicine residency at Barnes Hospital 
and serving as chief resident. Parker took 
emeritus status in 1998, but continued to 
work in his lab. 
Thomas H. Steinberg, MD
 Steinberg, associate professor of medicine, 
died Sunday, June 16, 2013, in St. Louis of 
complications from amyotrophic lateral  
sclerosis. He was 61. A cell biology 
researcher and infectious diseases physician, 
Steinberg joined the School of Medicine’s 
Division of Infectious Diseases in 1989. 
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Not many art careers begin in a pathology lab. As a teenager, Marilynne Bradley illustrated a  
lab’s blood chemistry book, helping her earn a chemistry scholarship to Washington University. 
She studied pre-med, but eventually committed fully to art. The Webster Groves (Mo.) Arts 
Commission recently presented Bradley, FA ’60 — a watercolorist, illustrator, historian and 
educator — with its Lifetime Achievement in the Arts Award and St. Louis Mayor Francis Slay 
declared Oct. 11, 2013, “Marilynne Bradley Day.” Her works are showcased around the world  
in museum exhibits and corporate collections. Following cataract surgery at the Center  
for Advanced Medicine, Bradley saw the Medical Center through fresh eyes. The resulting  
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